Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avalo Therapeutics (AVTX) Share-based Compensation (2016 - 2025)

Avalo Therapeutics (AVTX) has disclosed Share-based Compensation for 12 consecutive years, with $3.2 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Share-based Compensation rose 70.67% year-over-year to $3.2 million, compared with a TTM value of $12.0 million through Sep 2025, up 222.69%, and an annual FY2024 reading of $5.9 million, up 68.31% over the prior year.
  • Share-based Compensation was $3.2 million for Q3 2025 at Avalo Therapeutics, up from $2.7 million in the prior quarter.
  • Across five years, Share-based Compensation topped out at $5.3 million in Q1 2022 and bottomed at $471000.0 in Q2 2024.
  • Average Share-based Compensation over 5 years is $1.8 million, with a median of $1.4 million recorded in 2021.
  • The sharpest move saw Share-based Compensation plummeted 83.9% in 2023, then skyrocketed 477.07% in 2025.
  • Year by year, Share-based Compensation stood at $1.9 million in 2021, then tumbled by 55.44% to $843000.0 in 2022, then dropped by 7.95% to $776000.0 in 2023, then surged by 274.23% to $2.9 million in 2024, then grew by 8.61% to $3.2 million in 2025.
  • Business Quant data shows Share-based Compensation for AVTX at $3.2 million in Q3 2025, $2.7 million in Q2 2025, and $3.2 million in Q1 2025.